These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 23245752)

  • 1. Design and synthesis of new tripeptide-type SARS-CoV 3CL protease inhibitors containing an electrophilic arylketone moiety.
    Konno S; Thanigaimalai P; Yamamoto T; Nakada K; Kakiuchi R; Takayama K; Yamazaki Y; Yakushiji F; Akaji K; Kiso Y; Kawasaki Y; Chen SE; Freire E; Hayashi Y
    Bioorg Med Chem; 2013 Jan; 21(2):412-24. PubMed ID: 23245752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and biological evaluation of novel dipeptide-type SARS-CoV 3CL protease inhibitors: structure-activity relationship study.
    Thanigaimalai P; Konno S; Yamamoto T; Koiwai Y; Taguchi A; Takayama K; Yakushiji F; Akaji K; Kiso Y; Kawasaki Y; Chen SE; Naser-Tavakolian A; Schön A; Freire E; Hayashi Y
    Eur J Med Chem; 2013 Jul; 65():436-47. PubMed ID: 23747811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds: design, synthesis, biological evaluation, and docking studies.
    Thanigaimalai P; Konno S; Yamamoto T; Koiwai Y; Taguchi A; Takayama K; Yakushiji F; Akaji K; Chen SE; Naser-Tavakolian A; Schön A; Freire E; Hayashi Y
    Eur J Med Chem; 2013 Oct; 68():372-84. PubMed ID: 23994330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CL(pro) inhibitors.
    Regnier T; Sarma D; Hidaka K; Bacha U; Freire E; Hayashi Y; Kiso Y
    Bioorg Med Chem Lett; 2009 May; 19(10):2722-7. PubMed ID: 19362479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of a series of serine derivatives as small molecule inhibitors of the SARS coronavirus 3CL protease.
    Konno H; Wakabayashi M; Takanuma D; Saito Y; Akaji K
    Bioorg Med Chem; 2016 Mar; 24(6):1241-54. PubMed ID: 26879854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies.
    Tsai KC; Chen SY; Liang PH; Lu IL; Mahindroo N; Hsieh HP; Chao YS; Liu L; Liu D; Lien W; Lin TH; Wu SY
    J Med Chem; 2006 Jun; 49(12):3485-95. PubMed ID: 16759091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease.
    Shao YM; Yang WB; Kuo TH; Tsai KC; Lin CH; Yang AS; Liang PH; Wong CH
    Bioorg Med Chem; 2008 Apr; 16(8):4652-60. PubMed ID: 18329272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and Biochemical Evaluation of 8
    Wu J; Feng B; Gao LX; Zhang C; Li J; Xiang DJ; Zang Y; Wang WL
    Molecules; 2022 May; 27(10):. PubMed ID: 35630836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based drug design and structural biology study of novel nonpeptide inhibitors of severe acute respiratory syndrome coronavirus main protease.
    Lu IL; Mahindroo N; Liang PH; Peng YH; Kuo CJ; Tsai KC; Hsieh HP; Chao YS; Wu SY
    J Med Chem; 2006 Aug; 49(17):5154-61. PubMed ID: 16913704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.
    Akaji K; Konno H
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biflavonoids from Torreya nucifera displaying SARS-CoV 3CL(pro) inhibition.
    Ryu YB; Jeong HJ; Kim JH; Kim YM; Park JY; Kim D; Nguyen TT; Park SJ; Chang JS; Park KH; Rho MC; Lee WS
    Bioorg Med Chem; 2010 Nov; 18(22):7940-7. PubMed ID: 20934345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovering severe acute respiratory syndrome coronavirus 3CL protease inhibitors: virtual screening, surface plasmon resonance, and fluorescence resonance energy transfer assays.
    Chen L; Chen S; Gui C; Shen J; Shen X; Jiang H
    J Biomol Screen; 2006 Dec; 11(8):915-21. PubMed ID: 17092912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rational approach toward COVID-19 main protease inhibitors via molecular docking, molecular dynamics simulation and free energy calculation.
    Keretsu S; Bhujbal SP; Cho SJ
    Sci Rep; 2020 Oct; 10(1):17716. PubMed ID: 33077821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy.
    Pillaiyar T; Manickam M; Namasivayam V; Hayashi Y; Jung SH
    J Med Chem; 2016 Jul; 59(14):6595-628. PubMed ID: 26878082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of anti-coxsackievirus agents targeting 3C protease.
    Kim BK; Kim JH; Kim NR; Lee WG; Lee SD; Yun SH; Jeon ES; Kim YC
    Bioorg Med Chem Lett; 2012 Nov; 22(22):6952-6. PubMed ID: 23062551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of broad-spectrum halomethyl ketone inhibitors against coronavirus main protease 3CL(pro).
    Bacha U; Barrila J; Gabelli SB; Kiso Y; Mario Amzel L; Freire E
    Chem Biol Drug Des; 2008 Jul; 72(1):34-49. PubMed ID: 18611220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and evaluation of phenylisoserine derivatives for the SARS-CoV 3CL protease inhibitor.
    Konno H; Onuma T; Nitanai I; Wakabayashi M; Yano S; Teruya K; Akaji K
    Bioorg Med Chem Lett; 2017 Jun; 27(12):2746-2751. PubMed ID: 28454669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding interaction of quercetin-3-beta-galactoside and its synthetic derivatives with SARS-CoV 3CL(pro): structure-activity relationship studies reveal salient pharmacophore features.
    Chen L; Li J; Luo C; Liu H; Xu W; Chen G; Liew OW; Zhu W; Puah CM; Shen X; Jiang H
    Bioorg Med Chem; 2006 Dec; 14(24):8295-306. PubMed ID: 17046271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization Rules for SARS-CoV-2 M
    Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, docking studies, and evaluation of pyrimidines as inhibitors of SARS-CoV 3CL protease.
    Ramajayam R; Tan KP; Liu HG; Liang PH
    Bioorg Med Chem Lett; 2010 Jun; 20(12):3569-72. PubMed ID: 20494577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.